ClinicalTrials.gg
RecruitingNCT06723899CanWorkUpdated Dec 17, 2024

Testing the Effectiveness of a Work Rehabilitation Intervention for Women with Breast Cancer

An interventional study of CanWork in Breast Cancer, sponsored by University of Dublin, Trinity College. Recruiting at 2 sites in Ireland. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-12-17.

Sponsored by University of Dublin, Trinity College · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Started Nov 2024; still recruiting 1 year 11 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
248
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
Female
01

Study summary

Women with breast cancer make up a significant proportion of cancer survivors, with more than 43,750 women living with breast cancer in Ireland. However, many women report physical and psychological health difficulties that interfere with their ability to return to work. In Ireland, and internationally, these difficulties are being increasingly recognised, with recent research identifying gaps in rehabilitation services to prepare women with breast cancer to return to work. Collaborating with women with breast cancer, and those who provide health and supportive services to individuals living with cancer in Ireland, an online self-management intervention, CanWork, was developed. CanWork aims to support women with breast cancer to manage the process of returning to work and learn strategies to manage post-treatment health-related difficulties. CanWork also provides information on workplace entitlements. This intervention was trialled with women with breast cancer in 2021, who reported that the programme gave them confidence to return to work and that the content was relevant. This study will include a larger group of women with breast cancer to determine if CanWork is effective in supporting return to work. To do this, 248 women with breast cancer will be included in the study, half of whom will receive CanWork and the results will be compared with women who do not receive the intervention. Having a programme that is financially viable is important and therefore the costs involved in running and attending the intervention will also be calculated. Should this study demonstrate that CanWork is effective in supporting women with breast cancer to return to work, the study team will collaborate with cancer services in Ireland to make the programme available nationally.

Read the detailed description

The importance of supporting return to work (RTW) following a cancer diagnosis is increasingly recognised nationally and internationally. Other countries including the United Kingdom, Canada, and the United States, have also identified the importance of addressing work outcomes for those living with and beyond cancer. The goal for many cancer survivors is to optimise quality of life, including return to work. A recent report by the European Commission recommended that assessment and interventions for enhancing return to work for those with cancer should be integral parts of the survivorship pathway. As survivor numbers continue to increase the economic benefit of individuals returning to work will be considerable.

Breast cancer is now the most common cancer worldwide. In Ireland, the National Cancer Strategy (2017-2026) identified that 23% of all cancer survivors are comprised of women with breast cancer. The impact of disease and treatment-related side effects on work ability of women with breast cancer include cancer-related fatigue, pain, reduced cognitive function, anxiety, and depression. Therefore research is recommended for the development and evaluation of interventions to support women living with and beyond breast cancer to return to, and manage cancer related symptoms at, work.

CanWork is an online, occupational therapy self-management intervention that was designed in collaboration with women with breast cancer, healthcare professionals, cancer service providers and Health Service Executive staff with responsibility for development and delivery of cancer services in Ireland. Self-efficacy is the underlying theory of self-management interventions. Self-efficacy is the belief individuals have in their ability to change and take the necessary actions to make those changes. Perceived self-efficacy forms the basis of any decision to act and is defined as the perception of one's own ability to implement behaviours to attain designated types of outcomes such as improved health and well-being.

The primary aim of CanWork is to facilitate development of knowledge and skills to manage cancer-related symptoms that interfere with return to work. It consists of five, 90-minute group-based meetings and a once-off single individual meeting between the occupational therapist facilitator and each participant. Each of the group-based sessions consists of two components. The first component focuses on education and peer-led discussion of cancer-related symptom management and supports available to manage difficulties in work. The topics covered each week include managing fatigue in work, understanding cancer-related cognitive impairments, strategies for managing physical and mental health in work and effective communication with employers and colleagues.

Feasibility testing of CanWork demonstrated strong uptake for, and acceptability of, the intervention. The aim of this study, therefore, is to test the effectiveness of the CanWork intervention in facilitating women with breast cancer to return to work.

Methods

Study design A Cluster randomised trial (CRT) will be used to test the effectiveness of the CanWork intervention. The CRT will be carried out within the Medical Research Council (MRC) Framework for the development and evaluation of complex interventions to improve health outcomes for individuals with chronic health difficulties. The CONSORT guidelines extension for cluster randomised trials for the design and reporting of randomized controlled trials at all stages from recruitment of cancer centres (study clusters) and individual participants, randomisation, data collection, analysis and reporting will be used. (www.equator-network.org)

The units of randomisation for this study are Community Cancer Support Centres. In Ireland Community Cancer Support Centres (CCSC) are recognised as an essential part of provision of support for individuals with cancer, their families and carers. They provide a range of services from the provision of information, psychological support and survivorship programmes, to complementary therapies, yoga, relaxation classes, support groups, financial advice and drop-in services. CCSC operate in the charity sector and mainly rely on fund-raising activities to fund delivery of their services but they also receive project-based governmental funding.

Study sample The sample size required for this study is 248 women with breast cancer. This is based on detecting a 22% difference in return-to-work rates between the control and intervention clusters.

Data collection

This study will use two primary outcome measures:

Return to work: Yes/No. Return to Work Self-efficacy (RTW-SE) questionnaire

Secondary measures will examine readiness to return to work, self-efficacy for managing cancer-related symptoms that interfere with work, breast cancer specific quality of life measures, and a log book of work attendance. Cost effectiveness measures include EQ-5D-5L, ICECAP-A capability measure, work log book and cost of intervention delivery.

Data analysis

Quantitative Data Analysis

Analysis will be based primarily on intention-to-treat comparing outcomes at baseline and post-intervention follow-up periods. A per protocol analysis will be conducted as sensitivity analysis only. Descriptive analyses will include frequencies (%), means (standard deviation, 95%CI) and medians (inter-quartile range, IQR) where appropriate. A baseline table of characteristics for all participants recruited and by sites recruiting will be presented to ensure balance achieved with randomisation. Numbers of those recruited from participating CCSC, numbers (percentage) of those randomised and enrolled into intervention, and numbers (percentage) adhering to the intervention and retained in the study will be examined.

Qualitative data analysis All interviews will be audiotaped and transcribed verbatim. Analysis will be carried out using a computer software package, NVivo (available through TCD IS services). A content analysis approach will be used to explore commonalities between participants on their experiences of the intervention and to identify differences in experiences and opinions of the intervention. Within a content-analysis framework, both a deductive and inductive approach will be used for the analysis to identify new findings related to the CanWork intervention (inductive analysis) and to compare the findings of this study to previously reported research on work-focused interventions (i.e. deductive analysis).

Cost effectiveness analysis The health economics analysis will consist of trial-based economic evaluation and will incorporate cost utility analysis to compare the alternative strategies: (1) the CanWork self-management intervention; and (2) usual practice. The economic evaluation will be undertaken in a manner consistent with the guidelines issued by Health Information and Quality Authority (HIQA) for the evaluation of healthcare interventions and technologies in Ireland. The basic tasks of the evaluation are to identify, measure, value and compare the costs and outcomes of the alternatives being considered.

02

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Breast cancer
  • Self-Management intervention
  • Occupational Therapy
  • Self-Efficacy
  • Return to work
  • Symptom management
03

In context

Breast Neoplasms

14,825 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

This study's planned enrollment of 248 is above the median of 72 across 10,896 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

University of Dublin, Trinity College is the lead sponsor of 73 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women with confirmed diagnosis of breast cancer
  • Women with breast cancer who were in paid employment prior to their cancer diagnosis
  • Women with breast cancer who have completed oncology treatment (excluding hormone therapy, targeted and biological therapies) within the last 12 months
  • Women with breast cancer who have capacity to participate in a six-week online occupational therapy intervention

Exclusion criteria

Exclusion Criteria:

  • Women with breast cancer
  • Women with breast cancer who were not in paid employment prior to their cancer diagnosis
  • Women with breast cancer who have decided not to return to work following completion of cancer treatment
  • Women with breast cancer who have co-morbidity that would interfere with capacity to participate in a six-week online occupational therapy intervention
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumour. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
248 participants (estimated)

Study arms

  • Experimental
    Intervention arm

    The intervention arm will receive an online occupational therapy intervention, CanWork, to increase knowledge and skills of women with breast cancer to manage cancer-related symptoms that interfere with return to work. It consists of five, 90-minute group-based modules and an individual meeting between the occupational therapist facilitator and each participant. Each of the group-based modules consists of two components. The first component focuses on education and peer-led discussion of cancer-related symptom management and supports available to manage difficulties in work. Topics covered each week include managing fatigue in work, understanding cancer-related cognitive impairments, strategies for managing physical and mental health in work and effective communication with employers and colleagues.

    Other: CanWork

  • No intervention
    Comparator group

    This group will act as a comparison group to the intervention arm. Study participants (women with breast cancer) in this group will not receive the CanWork intervention but will receive standard supportive care provided in their local community cancer support centre

Interventions

  • OtherCanWork

    CanWork is an online, occupational therapy intervention to develop knowledge and skills to manage cancer-related symptoms that interfere with return to work. It consists of five, 90-minute group-based modules and an individual meeting between the occupational therapist facilitator and each participant. Each of the five-week group-based modules consists of two components: (i) education and peer-led discussion of cancer-related symptom management and supports available to manage difficulties in work and (ii) goal setting to facilitate application of knowledge and skills to work-related activities. Weekly topics include managing fatigue in work, understanding cancer-related cognitive impairments, strategies for managing physical and mental health in work and effective communication with employers and colleagues. The individual meeting between each participant and the occupational therapist is focused on designing a tailored return to work plan for each participant.

06

What researchers measure

Primary outcomes

  1. Return to work: Yes/No.

    The primary outcomes measure used in the feasibility study of CanWork was a self-report binary question of "Return to Work (RTW): Yes/No. This measure was identified in a systematic review as the most commonly used work-related measure in the included studies. RTW refers to any work resumption irrespective of number of hours a participant worked before their diagnosis. Participants will be asked immediately post-intervention, at three, six and 12-month follow-up periods if they have returned to work, on what date they returned and number of hours/week currently working

    Time frame: From enrolment to 12-months following enrolment

  2. Return to Work Self-efficacy (RTW-SE) questionnaire

    The RTW-SE measure is a short ten-item questionnaire that asks participants to rate their level of confidence on a Likert scale of 1-10 to manage physical, psychological and emotional demands of work. Recent research has found that both the baseline RTW-SE score and subsequent increases in the RTW-SE score during return-to-work interventions are robust predictors of return to work.

    Time frame: From enrolment to 12-months following enrolment

Secondary outcomes

  1. Readiness to return to work

    Participants will rate their current perceived readiness to return to work on a 10-point Likert scale: 0 (not at all ready) to 10 (extremely ready).

    Time frame: From enrolment to 12-months following enrolment

  2. Return to Work log book

    All participants (intervention and control group) who have returned to work will be required to keep a work-related logbook over a 12-month period following enrolment into the CanWork study. This logbook will record any absences (planned or unplanned) from work for cancer-related reasons. The following information will be collected: Dates of absenteeism Reason for absenteeism Date returned to work Total time absent from work

    Time frame: From enrolment to 12-months following enrolment

  3. EORTC QLQ-30

    Health related quality of life will be measured using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) with the relevant subscale for breast cancer QLQ-BR23. The EORTC-QLQ-C30 includes 30 items embedded over nine scales: five functional scales (physical, role, cognitive, emotional, and social functioning), three symptom scales (fatigue, pain, nausea and vomiting), and a global health status quality of life scale. Six single-items assess financial difficulties and symptoms commonly reported by those living with and beyond cancer: dyspnoea, insomnia, appetite loss, constipation and diarrhoea. The QLQ-BR23 questionnaire comprises of 23-items and is categorised into functional scales and symptom scales. Functional scales include items on body image, sexual functioning, sexual enjoyment, and future perspective. Future perspective explores the extent to which a participant is worried about their health in the future.

    Time frame: From enrolment to 12-months following enrolment

  4. PROMIS Self-Efficacy for Managing Symptoms

    The PROMIS Self-Efficacy for Managing Symptoms is an eight-item measure that examines participants' confidence in managing their symptoms in different settings (home, work and public places) and in preventing their symptoms from interfering with their personal activities, work and relationships. This measure has been calibrated across a number of different chronic diseases and demonstrates strong internal consistency and validity.

    Time frame: From enrolment to 12-months following enrolment

Other outcomes

  1. ICECAP-A (ICEpop CAPability measure for Adults)

    ICECAP-A is designed to assess overall quality of life and well-being of adults. It focuses on broader life aspects rather than just health-related factors. The measure is based on the concept of capability, which considers what individuals are able to do in their lives, encompassing a range of attributes that contribute to a fulfilling life. ICECAP-A evaluates five key dimensions of capability: Stability Attachment, Autonomy, Achievement and Enjoyment. Respondents rate their level of capability in each dimension, providing a comprehensive picture of their overall well-being. The ICECAP-A total score will be converted to a utility score to assess cost effectiveness of CanWork.

    Time frame: From study enrolment to 12-months following enrolment

07

Study locations

2 of 2 sites recruiting
  • Cancer Care West
    Galway, Ireland
    Recruiting
  • Solas Cancer Support Centre
    Waterford, Ireland
    Recruiting
    • Tracy M McDaid, MSc · Contactinfo@solascentre.ie · +353 51 304604
    • Tracy McDaid, MSc · Contact
08

References and documents

Individual participant data

Plan to share: No — Ethical approval has not been obtained to share IPD

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Sep 2027, 34 months after the start.

Of 2,661 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 34 months is close to that.

Counting every sponsor, half of 2,771 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2024
First posted
Dec 9, 2024
StartActual
Nov 13, 2024
Primary completionEst.
Sep 30, 2027
CompletionEst.
Mar 31, 2028
Last update
Dec 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06723899
Lead sponsor
University of Dublin, Trinity College
Collaborators
National Cancer Control Programme, Ireland, Royal College of Surgeons, Ireland, University of Galway
Responsible party
Deirdre Connolly (Professor in Occupational Therapy, University of Dublin, Trinity College) — Principal investigator
First posted
Dec 9, 2024
Start date
Nov 13, 2024
Primary completion
Sep 30, 2027 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
Dec 17, 2024

Study contacts

Deirdre Connolly, PhD
Contact
connoldm@tcd.ie
018963216
Nickola Pallin, PhD
Contact
palinn@tcd.ie
018963216
Deirdre Connolly, PhD
principal investigator · University of Dublin, Trinity College

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion